EUVIMEDObjevte EUVIMED
Crossref

Fidaxomicin: novel antibiotic for Clostridium difficile infection

Steve Chaplin, Mark Wilcox

Prescriber · 2013

DOI: 10.1002/psb.1002 ↗

At a glance

Journal article in Prescriber, 2013. Written by Steve Chaplin and 1 co-authors.

AbstraktBibliografické údajeCiteRelated studies

Abstract (original language)

Fidaxomicin (Dificlir) is a new antibiotic licensed for the treatment of C. difficile infection in adults. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse events and Professor Mark Wilcox discusses its place in treatment.

Cite

APA

Chaplin, S., & Wilcox, M. (2013). Fidaxomicin: novel antibiotic for Clostridium difficile infection. Prescriber. https://doi.org/10.1002/psb.1002

Vancouver

Chaplin S, Wilcox M. Fidaxomicin: novel antibiotic for Clostridium difficile infection. Prescriber. 2013. doi:10.1002/psb.1002

BibTeX
@article{Chaplin2013,
  author = {Chaplin, Steve and Wilcox, Mark},
  title = {Fidaxomicin: novel antibiotic for Clostridium difficile infection},
  journal = {Prescriber},
  year = {2013},
  doi = {10.1002/psb.1002}
}
Start for free →